Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ALEXANDER HU

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1306145859
CMS profile
1399272
Location
FLAGSTAFF, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$3,218.18

151 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,218.18 151

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ALEXANDER HU

NPI 1306145859 · CMS profile ID 1399272

Allopathic & Osteopathic Physicians / Internal Medicine

FLAGSTAFF, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1306145859?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ALEXANDER HU, NPI 1306145859, CMS profile ID 1399272. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1306145859?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). ALEXANDER HU, NPI 1306145859, CMS profile ID 1399272. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1306145859?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
ALEXANDER HU, NPI 1306145859, CMS profile ID 1399272, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1306145859?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

151 matching records · $3,218.18 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 151 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 151.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Teva Pharmaceuticals USA, Inc. $17.9108/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151735159 CMS
Fresenius Kabi USA, LLC $21.8708/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146953324 CMS
ABBVIE INC. $9.4808/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103946915 CMS
UCB, Inc. $37.1108/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143180801 CMS
Actelion Pharmaceuticals US, Inc. $19.4308/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078864407 CMS
GENZYME CORPORATION $31.8508/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139843517 CMS
Amgen Inc. $26.3708/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111602408 CMS
UCB, Inc. $26.5008/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143180796 CMS
ABBVIE INC. $14.9808/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103946913 CMS
Organon Llc $24.6708/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136286909 CMS
ABBVIE INC. $8.0608/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103946911 CMS
Lilly USA, LLC $1.2608/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135996348 CMS
Lilly USA, LLC $27.1208/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136017437 CMS
Amgen Inc. $8.6507/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111602384 CMS
Amgen Inc. $18.7907/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111602450 CMS
Amgen Inc. $14.4507/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111602430 CMS
ABBVIE INC. $23.3307/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103946909 CMS
ABBVIE INC. $10.0807/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103946907 CMS
ABBVIE INC. $3.0507/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103946905 CMS
Amgen Inc. $3.5607/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111602444 CMS
Amgen Inc. $14.7407/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111602446 CMS
Amgen Inc. $0.3207/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111602448 CMS
Lilly USA, LLC $23.5006/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136018600 CMS
Organon Llc $26.2606/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136286906 CMS
Fresenius Kabi USA, LLC $14.9306/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146953314 CMS
Amgen Inc. $23.8706/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111602442 CMS
ABBVIE INC. $20.4806/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103946903 CMS
Janssen Biotech, Inc. $23.1506/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078273907 CMS
Mallinckrodt Hospital Products Inc. $13.7906/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145084625 CMS
Teva Pharmaceuticals USA, Inc. $19.1506/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151735109 CMS
Amgen Inc. $16.9006/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111602428 CMS
UCB, Inc. $17.0006/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143180792 CMS
Amgen Inc. $24.5406/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111602440 CMS
Lilly USA, LLC $20.1406/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136017433 CMS
Amgen Inc. $22.9206/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111602406 CMS
Kyowa Kirin, Inc. $21.2505/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127024316 CMS
ABBVIE INC. $20.5805/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103946901 CMS
UCB, Inc. $15.0905/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143180787 CMS
ABBVIE INC. $20.2105/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103946899 CMS
GENZYME CORPORATION $27.2105/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139843487 CMS
ANI Pharmaceuticals, Inc. $22.6105/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091132117 CMS
Organon Llc $24.7905/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136286913 CMS
Amgen Inc. $15.4305/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111602404 CMS
Amgen Inc. $23.1505/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111602438 CMS
Amgen Inc. $6.9505/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111602382 CMS
Janssen Biotech, Inc. $30.1205/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078273939 CMS
ABBVIE INC. $17.4305/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103946895 CMS
ABBVIE INC. $1.4905/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103946897 CMS
ABBVIE INC. $31.6005/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103946893 CMS
Amgen Inc. $13.7505/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111602426 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,442.32 192
PY2020 $4,673.92 174
PY2021 $2,873.21 191
PY2022 $3,134.39 176
PY2023 $3,537.38 163
PY2024 $3,218.18 151
PY2025 $2,514.10 103

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $538,578.32 61
PY2024 Recipient $104.58 1
PY2024 Principal investigator $523,734.85 34
PY2023 Principal investigator $154,010.39 32
PY2022 Recipient $38.00 1
PY2022 Principal investigator $143,194.34 64
PY2021 Principal investigator $377,793.30 94
PY2020 Recipient $69.30 2
PY2020 Principal investigator $271,078.37 40
PY2019 Recipient $17,134.64 1
PY2019 Principal investigator $37,030.77 9

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

61 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $400.00 12/22/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY RE
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175396227
Principal investigator 1 Janssen Research & Development, LLC $6,400.00 12/19/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY RE
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175396245
Principal investigator 1 ABBVIE INC. $4,611.25 12/04/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202527590
Principal investigator 1 ABBVIE INC. $2,870.00 11/20/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202525000
Principal investigator 1 GlaxoSmithKline, LLC. $309.00 11/12/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS RHEUMATOLOGY ASSOCIATES PC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192098845
Principal investigator 1 GlaxoSmithKline, LLC. $570.00 11/12/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS RHEUMATOLOGY ASSOCIATES PC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192098870
Principal investigator 1 GlaxoSmithKline, LLC. $2,482.00 11/05/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS RHEUMATOLOGY ASSOCIATES PC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192150472
Principal investigator 1 ABBVIE INC. $2,241.50 11/04/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202521071
Principal investigator 1 ABBVIE INC. $453.60 10/23/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202518421
Principal investigator 1 GlaxoSmithKline, LLC. $3,500.00 10/08/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS RHEUMATOLOGY ASSOCIATES PC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192150455
Principal investigator 1 GlaxoSmithKline, LLC. $3,330.00 10/02/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS RHEUMATOLOGY ASSOCIATES PC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192098851
Principal investigator 1 Amgen Inc. $5,262.57 09/18/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY ASSOCIATES - FLAGSTAFF - 399 S MALPAIS LN
A Multicenter, Open-Label, Long-term, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjgren's Syndrome (SS) No dispute reported 06/30/2026 1246639193
Principal investigator 1 GlaxoSmithKline, LLC. $2,723.00 09/03/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS RHEUMATOLOGY ASSOCIATES PC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192098839
Principal investigator 1 GlaxoSmithKline, LLC. $103.00 09/03/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS RHEUMATOLOGY ASSOCIATES PC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192188832
Principal investigator 1 Janssen Research & Development, LLC $4,452.00 09/01/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY RE SEARCH PLLC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175396116
Principal investigator 1 Eli Lilly and Company $137.04 08/26/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A PHASE 2A, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3541860 IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187874365
Principal investigator 1 GlaxoSmithKline, LLC. $136.00 08/26/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS RHEUMATOLOGY ASSOCIATES PC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192098834
Principal investigator 1 GlaxoSmithKline, LLC. $103.00 08/26/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS RHEUMATOLOGY ASSOCIATES PC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192098858
Principal investigator 1 Amgen Inc. $17,551.90 08/20/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A Multicenter, Open-Label, Long-term, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjgren's Syndrome (SS) No dispute reported 06/30/2026 1246639273
Principal investigator 1 GlaxoSmithKline, LLC. $600.00 08/11/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS RHEUMATOLOGY ASSOCIATES PC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192150468
Principal investigator 1 GlaxoSmithKline, LLC. $103.00 08/11/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS RHEUMATOLOGY ASSOCIATES PC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192150476
Principal investigator 1 GlaxoSmithKline, LLC. $136.00 08/11/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS RHEUMATOLOGY ASSOCIATES PC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192188835
Principal investigator 1 ABBVIE INC. $4,080.00 08/07/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202503657
Principal investigator 1 ABBVIE INC. $5,440.00 08/07/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202503659
Principal investigator 1 ABBVIE INC. $4,080.00 08/07/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202504067
Principal investigator 1 GlaxoSmithKline, LLC. $11,400.00 08/01/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS RHEUMATOLOGY ASSOCIATES PC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192150459
Principal investigator 1 ABBVIE INC. $450.00 07/28/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202500206
Principal investigator 1 ABBVIE INC. $226.80 07/10/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202497962
Principal investigator 1 Janssen Research & Development, LLC $1,285.00 07/07/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY RE SEARCH PLLC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175396138
Principal investigator 1 ABBVIE INC. $2,408.90 07/02/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202495685
Principal investigator 1 Amgen Inc. $71,404.23 07/02/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246639297
Principal investigator 1 GlaxoSmithKline, LLC. $5,201.00 07/02/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS RHEUMATOLOGY ASSOCIATES PC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192098865
Principal investigator 1 Eli Lilly and Company $14,000.00 06/23/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE-ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OVERWEIGHT OR OBESITY IN CLINICAL PRACTICE No dispute reported 06/30/2026 1187877153
Principal investigator 1 Eli Lilly and Company $115,276.00 06/16/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A PHASE 2A, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3541860 IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187873799
Principal investigator 1 GlaxoSmithKline, LLC. $9,706.00 06/04/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS RHEUMATOLOGY ASSOCIATES PC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192150464
Principal investigator 1 Janssen Research & Development, LLC $3,570.00 06/02/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY RE SEARCH PLLC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175396271
Principal investigator 1 Amgen Inc. $5,500.00 05/09/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants No dispute reported 06/30/2026 1246639313
Principal investigator 1 GlaxoSmithKline, LLC. $6,077.00 05/09/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS RHEUMATOLOGY ASSOCIATES PC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192098876
Principal investigator 1 Janssen Research & Development, LLC $4,261.00 04/28/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY RE SEARCH PLLC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175395889
Principal investigator 1 Eli Lilly and Company $3,754.01 04/23/2025 Non-covered Recipient Entity
AARA CLINICAL RESEARCH
A PHASE 2A, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3541860 IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187873531
Principal investigator 1 Janssen Research & Development, LLC $13,012.00 04/11/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY RE SEARCH PLLC
A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies (SPIREA) No dispute reported 06/30/2026 1175396214
Principal investigator 1 ABBVIE INC. $680.00 04/10/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202475802
Principal investigator 1 ABBVIE INC. $2,446.70 04/03/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202471733
Principal investigator 1 Amgen Inc. $46,324.69 04/02/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246639251
Principal investigator 1 GlaxoSmithKline, LLC. $6,512.00 04/02/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS RHEUMATOLOGY ASSOCIATES PC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192188828
Principal investigator 1 Janssen Research & Development, LLC $2,967.00 03/31/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY RE SEARCH PLLC
A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies (SPIREA) No dispute reported 06/30/2026 1175396208
Principal investigator 1 Eli Lilly and Company $8,029.00 03/25/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187877161
Principal investigator 1 ABBVIE INC. $186.52 03/20/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202465218
Principal investigator 1 Amgen Inc. $23,311.80 03/14/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY ASSOCIATES - FLAGSTAFF - 399 S MALPAIS LN
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgrens Syndrome With Moderate-to-Severe Systemic Disease Activity No dispute reported 06/30/2026 1246639195
Principal investigator 1 Eli Lilly and Company $26.40 03/10/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187876423
Principal investigator 1 ABBVIE INC. $2,241.50 03/07/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202461366
Principal investigator 1 AstraZeneca UK Limited $10,150.00 03/07/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOL
A Multicenter Randomized Double-blind Placebo-controlled Phase 3 Study Evaluating the Efficacy and Safety of Subcutaneous Anifrolumab in Adult Patients with Systemic Lupus Erythematosus No dispute reported 06/30/2026 1185537339
Principal investigator 1 ABBVIE INC. $101.25 03/06/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY ASSOCIATES PC
M19-944 - A Study to Evaluate Efficacy and Safety of Upadacitinib in Adult Participants With Axial Spondyloarthritis No dispute reported 06/30/2026 1202458200
Principal investigator 1 Janssen Research & Development, LLC $1,285.00 03/03/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY RE SEARCH PLLC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175395954
Principal investigator 1 ABBVIE INC. $2,126.75 02/06/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202448359
Principal investigator 1 Eli Lilly and Company $1,709.58 01/27/2025 Non-covered Recipient Entity
AARA CLINICAL RESEARCH
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187875053
Principal investigator 1 Janssen Research & Development, LLC $2,285.00 01/27/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY RE SEARCH PLLC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175396167
Principal investigator 1 Amgen Inc. $21,187.64 01/08/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY ASSOCIATES - FLAGSTAFF - 399 S MALPAIS LN
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246639197
Principal investigator 1 GlaxoSmithKline, LLC. $2,634.00 01/08/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS RHEUMATOLOGY ASSOCIATES PC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192150482
Principal investigator 1 Eli Lilly and Company $36,343.00 01/07/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187874635
Principal investigator 1 Eli Lilly and Company $28,423.69 01/03/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A RANDOMIZED, CONTROLLED PRAGMATIC PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187876447